- If you are wondering whether Insmed at around US$148.55 is still a sensible entry or hold after a strong run, the key question is how that price compares with its underlying value.
- The share price has seen a 5.5% decline over the last 7 days and a 15.6% decline over the last 30 days, even though the 1 year return is 85.9% and the 3 year return is very large.
- Recent attention on Insmed has centered on its position in the pharmaceuticals and biotech space and how the market is weighing its pipeline and competitive standing. This backdrop helps explain why the share price has pulled back in the short term while still sitting well above where it was a year ago.
- On our checklist of 6 valuation tests, Insmed scores a 4. This sets up a closer…
Crypto VCs Say AI Investment Is in Post-Hype Era
February 11, 2026
